Thyroid Hormones, Silencing Mediator for Retinoid and Thyroid Receptors and Prognosis in Primary Breast Cancer.
Adult
Aged
Aged, 80 and over
Biomarkers, Tumor
/ blood
Breast Neoplasms
/ blood
Disease-Free Survival
Female
Gene Expression Regulation, Neoplastic
/ genetics
Humans
Middle Aged
Neoplasm Recurrence, Local
/ blood
Nuclear Receptor Co-Repressor 2
/ blood
Prognosis
Thyroid Gland
/ metabolism
Thyroid Hormones
/ blood
Thyrotropin
/ blood
Thyroxine
/ blood
Triiodothyronine
/ blood
Breast cancer
FT3
FT4
TSH
prognosis
silencing mediator for retinoid and thyroid receptors
thyroid gland
Journal
Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988
Informations de publication
Date de publication:
Nov 2020
Nov 2020
Historique:
received:
21
09
2020
revised:
01
10
2020
accepted:
05
10
2020
entrez:
28
10
2020
pubmed:
29
10
2020
medline:
4
11
2020
Statut:
ppublish
Résumé
Silencing mediator of retinoid and thyroid receptors (SMRT) is a nuclear corepressor in thyroid and estrogen hormones pathways. The aim was to evaluate SMRT expression in relation to thyroid hormone levels and prognostic markers in breast cancer (BC). Serum and tumor tissues were obtained from 36 patients with benign breast disease (BBD) and 79 BC patients. SMRT expression was determined by immunohistochemistry. Free-triiodothyronine (FT3), free thyroxine (FT4) and thyroid-stimulating hormone (TSH) were measured in serum. Higher FT4, lower FT3/FT4 ratio and higher expression of SMRT were found in BC compared to BBD (for all p<0.001). In BC, increased SMRT expression was associated with lower FT3 (p=0.028), higher tumor grade (p=0.031), increased KI67 proliferation index (p=0.015), higher risk of recurrence (p=0.014) and shorter disease-free survival (p=0.006). In multivariate analysis, SMRT overexpression and below-median levels of TSH were independent prognostic factors in BC. Elevated FT4 and decreased FT3/FT4 in BC patients suggest a role for thyroid hormones in malignant transformation. SMRT tumor overexpression is associated with lower FT3 levels, tumor proliferative activity and an aggressive clinical course.
Sections du résumé
BACKGROUND/AIM
OBJECTIVE
Silencing mediator of retinoid and thyroid receptors (SMRT) is a nuclear corepressor in thyroid and estrogen hormones pathways. The aim was to evaluate SMRT expression in relation to thyroid hormone levels and prognostic markers in breast cancer (BC).
PATIENTS AND METHODS
METHODS
Serum and tumor tissues were obtained from 36 patients with benign breast disease (BBD) and 79 BC patients. SMRT expression was determined by immunohistochemistry. Free-triiodothyronine (FT3), free thyroxine (FT4) and thyroid-stimulating hormone (TSH) were measured in serum.
RESULTS
RESULTS
Higher FT4, lower FT3/FT4 ratio and higher expression of SMRT were found in BC compared to BBD (for all p<0.001). In BC, increased SMRT expression was associated with lower FT3 (p=0.028), higher tumor grade (p=0.031), increased KI67 proliferation index (p=0.015), higher risk of recurrence (p=0.014) and shorter disease-free survival (p=0.006). In multivariate analysis, SMRT overexpression and below-median levels of TSH were independent prognostic factors in BC.
CONCLUSION
CONCLUSIONS
Elevated FT4 and decreased FT3/FT4 in BC patients suggest a role for thyroid hormones in malignant transformation. SMRT tumor overexpression is associated with lower FT3 levels, tumor proliferative activity and an aggressive clinical course.
Identifiants
pubmed: 33109580
pii: 40/11/6417
doi: 10.21873/anticanres.14663
doi:
Substances chimiques
Biomarkers, Tumor
0
Nuclear Receptor Co-Repressor 2
0
Thyroid Hormones
0
Triiodothyronine
06LU7C9H1V
Thyrotropin
9002-71-5
Thyroxine
Q51BO43MG4
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
6417-6428Commentaires et corrections
Type : ErratumIn
Informations de copyright
Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.